FDA Compounding Committee Reviews Seven Research Peptides (July 2026)

FDA revisits peptides for compounding

On July 23-24, 2026, the U.S. Food and Drug Administration convened its Pharmacy Compounding Advisory Committee (PCAC) at the agency's White Oak campus in Silver Spring, Maryland. The two-day meeting focused on whether a group of well-known research peptides should be added to the Section 503A Bulk Drug Substances List, the list that governs which bulk substances compounding pharmacies may use.

Which compounds were on the agenda

The committee reviewed seven peptides in total. The first day covered BPC-157, KPV, TB-500, and MOTS-c. The second day covered emideltide (delta sleep-inducing peptide, or DSIP), Semax, and Epitalon. These compounds appear frequently in the research space, which is why the meeting drew close attention from suppliers, pharmacies, and researchers alike.

What the FDA proposed

Ahead of the meeting, the FDA released briefing materials that reached the same conclusion for each of the seven substances: it did not recommend adding them to the 503A list, citing gaps in the available safety and characterization data. The advisory committee reviews the evidence and votes, but its recommendations are advisory. The final determination rests with the FDA.

Why it matters for research

For laboratories, the takeaway is about classification, not clinical guidance. A listing decision under 503A is a regulatory determination about compounding; it is not an endorsement of any use. Compounds that are not on the list remain available strictly as research chemicals for in vitro and laboratory work. Nothing about the meeting changes the fact that these materials are supplied and handled for research use only.

What comes next

The FDA has signaled that the committee will meet again before the end of February 2027 to consider additional peptides, as part of a broader review of roughly a dozen substances. Researchers who follow this area should expect the regulatory picture to keep evolving, and should rely on primary FDA sources and peer-reviewed literature rather than secondhand summaries.

We will keep tracking these developments and update our research library as the committee's decisions are finalized.

Research use only — not for human consumption.